AUG 14, 2026 · JOURNAL ARTICLE
First-line immune checkpoint inhibitors versus chemotherapy in delaying quality of life deterioration in advanced NSCLC: a systematic review and meta-analysis
BMC Medicine
Rigorous systematic review and meta-analysis of 13 phase II–III RCTs with 6555 patients showing that ICI-based therapies significantly delay QoL deterioration versus chemotherapy, with low heterogeneity and prespecified outcomes, but surrogate endpoints rather than hard clinical outcomes.
Reported
Primary endpoint: HR for TTD of g…0.75 (95% CI 0.71–0.81)
p-value for primary endpoint<0.0001
Heterogeneity for primary endpointI2=0%